Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
690 Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression
Compose a Response to This Article
Other responses
No responses have been published for this article.